Cognition Therapeutics Inc (CGTX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Cognition Therapeutics reported revenue of $0. Net income was -$23.5M, or -$0.32 per diluted share. Operating activities generated -$24.6M of cash, leaving -$24.6M of free cash flow. At fiscal year end, Cognition Therapeutics held $48.4M in total assets against $14.1M in total liabilities, including $36.8M of cash and equivalents.
Open the full interactive Cognition Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Cognition Therapeutics Key Stats
| Share Price | $0.80 |
|---|---|
| Market Cap | $72.7M |
| 52-Week Range | $0.60 – $1.85 |
| Shares Outstanding | 90.6 million (basic, 2026 Q2) |
Cognition Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$28.6M | -$43.6M | -$50.7M | -$54.0M | -$47.8M |
| Pre-Tax Income | -$11.7M | -$21.4M | -$25.8M | -$34.0M | -$23.5M |
| Income Tax | — | $0 | $0 | $0 | $0 |
| Net Income | -$11.7M | -$21.4M | -$25.8M | -$34.0M | -$23.5M |
| Diluted EPS | -$3.13 | -$0.91 | -$0.86 | -$0.86 | -$0.32 |
Cognition Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$4.9M | -$3.3M | -$4.6M | -$3.9M |
| Diluted EPS | -$0.06 | -$0.05 | -$0.05 | -$0.04 |
Cognition Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $54.7M | $41.6M | $29.9M | $25.0M | $36.8M |
| Current Assets | $59.0M | $47.6M | $34.2M | $29.6M | $48.0M |
| Total Assets | $59.1M | $50.4M | $35.2M | $30.2M | $48.4M |
| Current Liabilities | $7.9M | $7.8M | $10.2M | $11.1M | $13.9M |
| Total Liabilities | $7.9M | $10.2M | $10.7M | $11.5M | $14.1M |
| Shareholders' Equity | $51.3M | $40.2M | $24.5M | $18.8M | $34.3M |
Cognition Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$3.6M | -$18.5M | -$16.0M | -$28.5M | -$24.6M |
| Cash From Investing | -$27,000 | -$171,000 | -$147,000 | -$4,000 | $9,000 |
| Cash From Financing | $53.2M | $5.5M | $4.5M | $23.6M | $36.6M |
| Free Cash Flow | -$3.7M | -$18.7M | -$16.2M | -$28.5M | -$24.6M |
Figures from Cognition Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Cognition Therapeutics financials page for every line item.
Cognition Therapeutics Company Profile
| Ticker | CGTX |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Purchase, New York |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001455365 |
Frequently Asked Questions
What was Cognition Therapeutics' revenue in fiscal 2025?
Cognition Therapeutics (CGTX) reported revenue of $0 for fiscal 2025.
What is Cognition Therapeutics' annual revenue history?
Cognition Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Cognition Therapeutics' net income in fiscal 2025?
Cognition Therapeutics reported net income of -$23.5M for fiscal 2025.
What was Cognition Therapeutics' earnings per share (EPS) in fiscal 2025?
Cognition Therapeutics' diluted EPS was -$0.32 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Cognition Therapeutics generate in fiscal 2025?
Cognition Therapeutics generated -$24.6M of free cash flow in fiscal 2025.
What was Cognition Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Cognition Therapeutics reported revenue of $0.
How many shares of Cognition Therapeutics are outstanding?
Cognition Therapeutics reported a weighted average of 90.6 million basic shares outstanding in 2026 Q2.
What is Cognition Therapeutics' market cap?
Based on its latest closing price, Cognition Therapeutics (CGTX) has a market capitalization of about $72.7M.
When does Cognition Therapeutics' fiscal year end?
Cognition Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Cognition Therapeutics headquartered?
Cognition Therapeutics lists its business address in Purchase, New York in its SEC filings.
Cognition Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →